Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group Study.

von Gruenigen VE, Huang HQ, Gil KM, Frasure HE, Armstrong DK, Wenzel LB.

Gynecol Oncol. 2012 Mar;124(3):379-82. doi: 10.1016/j.ygyno.2011.11.032. Epub 2011 Nov 23.

PMID:
22119995
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: a Gynecologic Oncology Group study.

von Gruenigen VE, Huang HQ, Gil KM, Gibbons HE, Monk BJ, Rose PG, Armstrong DK, Cella D, Wenzel L.

J Pain Symptom Manage. 2010 May;39(5):839-46. doi: 10.1016/j.jpainsymman.2009.09.022.

PMID:
20471545
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials.

von Gruenigen VE, Huang HQ, Gil KM, Gibbons HE, Monk BJ, Rose PG, Armstrong DK, Cella D, Wenzel L.

Cancer. 2009 Oct 15;115(20):4857-64. doi: 10.1002/cncr.24520.

PMID:
19691091
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.

Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D; Gynecologic Oncology Group.

J Clin Oncol. 2007 Feb 1;25(4):437-43.

PMID:
17264340
[PubMed - indexed for MEDLINE]
Free Article
5.

Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study.

Chase DM, Huang HQ, Wenzel L, Cella D, McQuellon R, Long HJ, Moore DH, Monk BJ.

Gynecol Oncol. 2012 May;125(2):315-9. doi: 10.1016/j.ygyno.2012.01.047. Epub 2012 Feb 1.

PMID:
22307062
[PubMed - indexed for MEDLINE]
6.

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group.

N Engl J Med. 2006 Jan 5;354(1):34-43.

PMID:
16394300
[PubMed - indexed for MEDLINE]
Free Article
7.

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.

Landrum LM, Java J, Mathews CA, Lanneau GS Jr, Copeland LJ, Armstrong DK, Walker JL.

Gynecol Oncol. 2013 Jul;130(1):12-8. doi: 10.1016/j.ygyno.2013.04.001. Epub 2013 Apr 8.

PMID:
23578540
[PubMed - indexed for MEDLINE]
8.

Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.

Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.

J Clin Oncol. 2006 Feb 1;24(4):579-86.

PMID:
16446330
[PubMed - indexed for MEDLINE]
Free Article
9.

The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.

Carey MS, Bacon M, Tu D, Butler L, Bezjak A, Stuart GC.

Gynecol Oncol. 2008 Jan;108(1):100-5. Epub 2007 Oct 24.

PMID:
17920108
[PubMed - indexed for MEDLINE]
10.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
[PubMed - indexed for MEDLINE]
11.

Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.

Reck M, Thatcher N, Smit EF, Lorigan P, Szutowicz-Zielinska E, Liepa AM, Winfree KB, Peterson P, Guba SC, Socinski MA.

Lung Cancer. 2012 Dec;78(3):276-81. doi: 10.1016/j.lungcan.2012.09.002. Epub 2012 Oct 6.

PMID:
23043970
[PubMed - indexed for MEDLINE]
12.

A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172.

Krivak TC, Tian C, Rose GS, Armstrong DK, Maxwell GL.

Gynecol Oncol. 2009 Oct;115(1):81-5. doi: 10.1016/j.ygyno.2009.06.021. Epub 2009 Jul 12.

PMID:
19596139
[PubMed - indexed for MEDLINE]
13.

Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.

Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL 2nd, Meisner BC, Armstrong DK, Frick KD.

Gynecol Oncol. 2007 Sep;106(3):476-81. Epub 2007 Aug 3.

PMID:
17688927
[PubMed - indexed for MEDLINE]
14.

Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.

Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, Reed NS, Nordal RR, Coens C, Vergote I; European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group.

Gynecol Oncol. 2013 Nov;131(2):437-44. doi: 10.1016/j.ygyno.2013.08.014. Epub 2013 Aug 27.

PMID:
23994107
[PubMed - indexed for MEDLINE]
15.

Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.

Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, DeLoia JA; Gynecologic Oncology Group Phase III Trial.

J Clin Oncol. 2008 Jul 20;26(21):3598-606. doi: 10.1200/JCO.2008.16.1323.

PMID:
18640939
[PubMed - indexed for MEDLINE]
Free Article
16.

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D.

Gynecol Oncol. 2006 Jan;100(1):27-32.

PMID:
16368440
[PubMed - indexed for MEDLINE]
17.

Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.

Konner JA, Grabon DM, Gerst SR, Iasonos A, Thaler H, Pezzulli SD, Sabbatini PJ, Bell-McGuinn KM, Tew WP, Hensley ML, Spriggs DR, Aghajanian CA.

J Clin Oncol. 2011 Dec 10;29(35):4662-8. doi: 10.1200/JCO.2011.36.1352. Epub 2011 Nov 7.

PMID:
22067389
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study.

Wenzel L, Huang HQ, Monk BJ, Rose PG, Cella D.

J Clin Oncol. 2005 Aug 20;23(24):5605-12.

PMID:
16110020
[PubMed - indexed for MEDLINE]
Free Article
19.

Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.

Rothenberg ML, Liu PY, Braly PS, Wilczynski SP, Hannigan EV, Wadler S, Stuart G, Jiang C, Markman M, Alberts DS.

J Clin Oncol. 2003 Apr 1;21(7):1313-9.

PMID:
12663720
[PubMed - indexed for MEDLINE]
20.

The effect of prolonged cycles of chemotherapy on quality of life in gynaecologic cancer patients.

Carter JR, Chen MD, Fowler JM, Carson LF, Twiggs LB.

J Obstet Gynaecol Res. 1997 Apr;23(2):197-203.

PMID:
9158308
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk